CureVac 6-K: Only AGM Vote Outcomes Disclosed, No Earnings Info

Rhea-AI Filing Summary

CureVac N.V. (CVAC) filed a Form 6-K to notify investors that it issued a press release on June 24, 2025 detailing the voting results from its Annual General Meeting of shareholders. No financial performance metrics, strategic transactions, or operational updates were included in the filing. The company also clarified that the information, including Exhibit 99.1 (the press release), is furnished—not filed—and therefore is not subject to Section 18 liabilities of the Exchange Act nor incorporated by reference into other SEC filings.

Insights

Corporate Governance Analyst

TL;DR: Routine governance disclosure; no direct financial impact disclosed.

This 6-K merely furnishes notice that CureVac released AGM voting outcomes. Without the actual vote breakdown—such as director re-election percentages or approval of compensation policies—investors cannot gauge shifts in shareholder sentiment. Given the absence of material financial data or strategy updates, the filing is procedural. Its primary value is confirming that governance resolutions were put to vote and that management complied with foreign-issuer disclosure norms.

Form 6-K: How Foreign Companies Report to the SEC →

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2025

 

Commission File Number: 001-39446

 

 

 

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x         Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes ¨          No x

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes ¨          No x

 

 

 

 

 

 

On June 24, 2025, CureVac N.V. (the “Company”) issued a press release announcing the voting results of the Company’s annual general meeting of shareholders.

 

The information included in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 	CureVac N.V.
 	(Registrant)
 	 
Date: June 24, 2025	By:	/s/ Alexander Zehnder
 	 	Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

EXHIBIT NO.	 	DESCRIPTION
99.1	 	CureVac N.V. Press Release dated June 24, 2025

 

 

 

FAQ

What did CureVac (CVAC) disclose in its June 24 2025 Form 6-K?

The company announced it issued a press release reporting AGM voting results.

Does the 6-K include CureVac’s financial performance or earnings data?

No. The filing contains no financial metrics or earnings information.

Is the information in CureVac’s 6-K considered "filed" under the Exchange Act?

No. The company states the information is "furnished," not "filed," avoiding Section 18 liability.

Where can investors find the detailed AGM voting results for CVAC?

The results are in Exhibit 99.1, CureVac’s press release dated June 24 2025.